Sign in or create an account to add this stock to your watchlist.
About Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660
Debt
Debt-to-Equity RatioN/A
Current Ratio12.44
Quick Ratio12.44
Price-To-Earnings
Trailing P/E Ratio-6.59
Forward P/E Ratio-11.58
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.43 per share
Price / Book3.64
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,570,000.00
Net MarginsN/A
Return on Equity-79.70%
Return on Assets-59.44%
Miscellaneous
Employees14
Outstanding Shares50,930,000
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics (NASDAQ:VKTX) issued its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.02. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
4 analysts have issued 12-month target prices for Viking Therapeutics' shares. Their predictions range from $8.00 to $11.00. On average, they expect Viking Therapeutics' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Viking Therapeutics.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Lexicon Pharmaceuticals (LXRX), Mirati Therapeutics (MRTX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Zai Lab (ZLAB), Endocyte (ECYT), Karyopharm Therapeutics (KPTI), Omeros (OMER), Eagle Pharmaceuticals (EGRX), CytomX Therapeutics (CTMX), Amarin (AMRN), MacroGenics (MGNX), OptiNose (OPTN), UroGen Pharma (URGN) and Abeona Therapeutics (ABEO).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 52)
- Mr. Michael Morneau, CFO & Principal Accounting Officer (Age 53)
- Mr. Gregory S. Zante CPA, VP of Fin. & Operations (Age 47)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Dr. Hiroko Masamune Ph.D., Sr. VP of Pharmaceutical Devel. (Age 61)
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Has Viking Therapeutics been receiving favorable news coverage?
Media coverage about VKTX stock has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.23 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.29 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Viking Therapeutics' major shareholders?
Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (3.13%), Millennium Management LLC (2.75%), Sio Capital Management LLC (2.51%), Opaleye Management Inc. (2.16%), Victory Capital Management Inc. (1.19%) and Park West Asset Management LLC (0.98%). View Institutional Ownership Trends for Viking Therapeutics.
Which major investors are selling Viking Therapeutics stock?
Which major investors are buying Viking Therapeutics stock?
VKTX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Opaleye Management Inc., Victory Capital Management Inc., BlackRock Inc., Iguana Healthcare Management LLC, Tibra Equities Europe Ltd, Spark Investment Management LLC and Trexquant Investment LP. View Insider Buying and Selling for Viking Therapeutics.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $5.21.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $265.36 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (VKTX)
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viking Therapeutics (NASDAQ:VKTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Viking Therapeutics in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 72.74%. The high price target for VKTX is $11.00 and the low price target for VKTX is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.00 | $9.00 | $7.00 | $5.6667 |
| Price Target Upside: | 72.74% upside | 95.23% upside | 13.27% upside | 104.57% upside |
Viking Therapeutics (NASDAQ:VKTX) Consensus Price Target History
Viking Therapeutics (NASDAQ:VKTX) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Viking Therapeutics (NASDAQ:VKTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Viking Therapeutics (NASDAQ VKTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 20.21%
Viking Therapeutics (NASDAQ VKTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/15/2016 | Matthew W Foehr | Director | Buy | 13,000 | $1.21 | $15,730.00 | 39,250 |  |
| 4/13/2016 | Matthew W Foehr | Director | Buy | 20,000 | $1.24 | $24,800.00 | 26,250 | |
(Data available from 1/1/2013 forward)
Viking Therapeutics (NASDAQ VKTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Lucky Seven: Exelixis Bounces Back, Global Blood Therapeutics Bleeds
seekingalpha.com - May 19 at 5:52 PM |
 | VKTX May 2018 2.500 call
finance.yahoo.com - May 18 at 8:43 AM |
 | Viking Therapeutics (VKTX) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 17 at 4:53 PM |
| FY2018 Earnings Estimate for Viking Therapeutics Issued By Zacks Investment Research (VKTX)
www.americanbankingnews.com - May 16 at 7:37 AM |
| VKTX: Enrollment of Phase 2 Trial of VK2809 Nearing Completion
finance.yahoo.com - May 14 at 5:19 PM |
| Viking Therapeutics (VKTX) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - May 12 at 1:10 AM |
| Maxim Group Reiterates $8.00 Price Target for Viking Therapeutics (VKTX)
www.americanbankingnews.com - May 10 at 7:51 PM |
| HC Wainwright Analysts Give Viking Therapeutics (VKTX) a $11.00 Price Target
www.americanbankingnews.com - May 10 at 7:05 PM |
| Viking Therapeutics (VKTX) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 6:29 PM |
| Viking Therapeutics' (VKTX) CEO Brian Lian on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:26 AM |
| Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:33 PM |
| Viking Therapeutics (VKTX) Forecasted to Earn Q1 2019 Earnings of ($0.13) Per Share
www.americanbankingnews.com - May 9 at 9:06 AM |
 | Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway
www.benzinga.com - May 9 at 8:20 AM |
| Q1 2018 Earnings Estimate for Viking Therapeutics Issued By William Blair (VKTX)
www.americanbankingnews.com - May 2 at 8:08 AM |
 | Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018
www.prnewswire.com - May 2 at 8:04 AM |
| William Blair Initiates Viking With An Outperform Rating After Competitor Proves Strategy
finance.yahoo.com - May 1 at 8:27 AM |
| Viking Therapeutics (VKTX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:26 AM |
| Viking Therapeutics a possible 10-bagger - William Blair
seekingalpha.com - April 30 at 5:13 PM |
| Viking Therapeutics (VKTX) Earns Outperform Rating from Analysts at William Blair
www.americanbankingnews.com - April 30 at 10:02 AM |
| Viking Therapeutics (VKTX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 30 at 9:49 AM |
| Zacks: Analysts Anticipate Viking Therapeutics (VKTX) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 24 at 3:10 PM |
| This Morning's Technical Outlook on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ...
www.prnewswire.com - April 24 at 8:20 AM |
| HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (VKTX)
www.americanbankingnews.com - April 17 at 11:58 PM |
| Viking Therapeutics (VKTX) Downgraded by ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM |
| What Should Investors Know About Viking Therapeutics Inc’s (NASDAQ:VKTX) Future?
finance.yahoo.com - April 13 at 5:31 PM |
| Viking Therapeutics (VKTX) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM |
| Why Viking Therapeutics, Inc. Stock Cratered in March
finance.yahoo.com - April 12 at 8:39 AM |
| Viking Therapeutics (VKTX) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - April 10 at 11:38 PM |
| Viking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 7 at 5:22 PM |
| Viking Therapeutics (VKTX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 2 at 10:52 PM |
| Viking Therapeutics (VKTX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 16 at 10:28 PM |
| VKTX: Data from Phase 2 Study of VK2809 in NASH in 2H18; Sufficient Cash to Fund Operations to 2020
finance.yahoo.com - March 9 at 6:49 PM |
 | Here's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today - Motley Fool
www.fool.com - March 9 at 8:21 AM |
| Viking Therapeutics (VKTX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - March 8 at 9:58 PM |
| Roth Capital Analysts Give Viking Therapeutics (VKTX) a $8.00 Price Target
www.americanbankingnews.com - March 8 at 7:43 PM |
 | Streetwise newsletter: Raging River’s search for relevance, RBC’s gender diversity ETFs
www.theglobeandmail.com - March 8 at 6:41 PM |
 | Here's Why Viking Therapeutics Dropped as Much as 17.3% Today
www.msn.com - March 8 at 6:41 PM |
| Here's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today
finance.yahoo.com - March 8 at 6:41 PM |
| Viking Therapeutics (VKTX) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 8 at 9:04 AM |
| Viking Therapeutics Reports Fourth Quarter and Year-End 2017 ... - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:24 AM |
| Viking Therapeutics' (VKTX) CEO Brian Lian on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 8 at 8:24 AM |
| Viking Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:33 PM |
| Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 6:33 PM |
| Viking Therapeutics to Present at Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - March 6 at 8:16 AM |
| Viking Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 6 at 8:16 AM |
| Viking Therapeutics (VKTX) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - March 1 at 8:14 PM |
| EAM Investors LLC Takes $2.54 Million Position in Viking Therapeutics Inc (VKTX)
www.americanbankingnews.com - February 28 at 2:14 PM |
| Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
finance.yahoo.com - February 28 at 8:18 AM |
| Acceleron Pharma (XLRN) versus Viking Therapeutics (VKTX) Head-To-Head Analysis
www.americanbankingnews.com - February 17 at 11:18 PM |
| Zacks: Brokerages Expect Viking Therapeutics Inc (VKTX) to Announce -$0.19 EPS
www.americanbankingnews.com - February 15 at 9:12 PM |
Viking Therapeutics (NASDAQ:VKTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Viking Therapeutics (NASDAQ:VKTX) Income Statement, Balance Sheet and Cash Flow Statement
Viking Therapeutics (NASDAQ VKTX) Stock Chart for Sunday, May, 20, 2018
Loading chart…
